Orthofix Investor Presentation Deck

Orthofix Q3 2023 Highlights (1) Constant Currency is calculated by applying foreign currency rates applicable to the comparable, prior-year period to present the current period net sales at comparable rates. Constant currency can be presented for numerous GAAP measures, but is commonly used by management to analyze net sales excluding the impact of changes in foreign currency rates. (2) The reasons for and nature of non-GAAP disclosures by the Company, descriptions of the adjustments used to calculate those non-GAAP financial measures, and reconciliations of those non-GAAP financial measures to the most comparable GAAP financial measure, are provided in the Company's press release issued and Current Report on Form 8-K filed on November 8, 2023. (3) See Appendix A for calculation of proforma Adjusted EBITDA and proforma Adjusted Gross Margin for each quarterly period of 2022. (4) Pro forma net sales for 2022 include the impact of final Spinal Implant stocking orders to European distributors prior to SeaSpine's exit from that market. Excluding the impact of these transactions, net sales growth was +7.4% on a pro forma constant currency basis for Total Orthofix and +5.8% for Spinal Implants, Biologics, and Enabling Technologies. $184M Q3 2023 Revenue 59.9% Growth YoY at Constant Currency(¹) 0.3% Proforma Growth YoY at Constant Currency(2)(4) $101M Q3 2023 Global Spinal Implants, Biologics and Enabling Technologies Revenue -6.1% Proforma Decline YoY at Constant Currency(2)(4) $33.7M Cash & Cash Equivalents, 9/30/2023 $70M of outstanding credit facility borrowings © 2023 Orthofix Medical Inc. All rights reserved | 14 $53.4M Q3 2023 BGT Revenue 14.7% Growth YoY $29.7M Q3 2023 Global Orthopedics Revenue 0.7% Growth YoY at Constant Currency (2) $13.5M Adjusted EBITDA 17.1% Proforma Growth YoY(2)(3) 71% Adjusted Gross Margin(2) ORTHOFIX® SeaSpine.

View entire presentation